» Articles » PMID: 33343725

Skin Manifestations in Spondyloarthritis

Overview
Date 2020 Dec 21
PMID 33343725
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a loss of efficacy of a current systemic treatment or can even be treatment associated. Cutaneous manifestations in SpA not only add additional morbidity with physical impact but also impose a psychosocial burden on affected patients. Psoriasis (PsO) - the main skin disease in SpA - has a variety of clinical presentations, including plaque-type PsO, inverse PsO, guttate PsO, erythrodermic PsO, nail PsO and pustular types. SpA associated with IBD presents with neutrophilic and granulomatous skin disorders, including pyoderma gangrenosum, hidradenitis suppurativa and cutaneous Crohn's disease. Reactive arthritides has a favourable prognosis and may feature keratoderma blenorrhagicum or balanitis circinatum as typical skin manifestations. Immunologically, SpA-associated skin diseases share interleukin (IL)-17 and IL-23 dysregulation but show distinctive genetic and immunological profiles. Therefore, they vary in their treatment responses to targeted therapies with biologicals or small molecules. In this review, we highlight the clinical presentation of skin manifestations in SpA and discuss therapeutic approaches in this interdisciplinary field.

Citing Articles

EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders.

Kuiper J, Prinz J, Stratikos E, Kusnierczyk P, Arakawa A, Springer S Ann Rheum Dis. 2023; 82(7):887-896.

PMID: 36987655 PMC: 10313995. DOI: 10.1136/ard-2022-222852.


Potential effects of shift work on skin autoimmune diseases.

Stenger S, Grasshoff H, Hundt J, Lange T Front Immunol. 2023; 13:1000951.

PMID: 36865523 PMC: 9972893. DOI: 10.3389/fimmu.2022.1000951.


Cutaneous and rheumatological manifestations of reactive arthritis: A case report.

Slouma M, Ben Dhia S, Dhahri R, Litaiem N, Metoui L, Gharsallah I Clin Case Rep. 2022; 10(11):e6542.

PMID: 36381024 PMC: 9637938. DOI: 10.1002/ccr3.6542.


The role of the multidisciplinary team in the management of psoriatic arthritis.

Jadon D, Helliwell P Musculoskeletal Care. 2022; 20 Suppl 1:S32-S40.

PMID: 36356109 PMC: 9828182. DOI: 10.1002/msc.1690.


[Granulomatous dermatoses].

Kinberger M, Bonnekoh H, Dilling A, Meier K Z Rheumatol. 2022; 81(7):577-586.

PMID: 35854155 DOI: 10.1007/s00393-022-01239-9.


References
1.
Goncalves M, Romao V, Soares-de-Almeida L, Canhao H, Romeu J, Kutzner H . Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. Acta Reumatol Port. 2017; 42(4):324-328. View

2.
Mease P, Gottlieb A, van der Heijde D, FitzGerald O, Johnsen A, Nys M . Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017; 76(9):1550-1558. PMC: 5561378. DOI: 10.1136/annrheumdis-2016-210724. View

3.
Ingram J, Collier F, Brown D, Burton T, Burton J, Chin M . British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2018; 180(5):1009-1017. DOI: 10.1111/bjd.17537. View

4.
Ashchyan H, Butler D, Nelson C, Noe M, Tsiaras W, Lockwood S . The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatol. 2018; 154(4):409-413. PMC: 5876860. DOI: 10.1001/jamadermatol.2017.5978. View

5.
Roure F, Elhai M, Burki V, Fabreguet I, Koumakis E, Payet J . Prevalence and clinical characteristics of psoriasis in spondyloarthritis: a descriptive analysis of 275 patients. Clin Exp Rheumatol. 2016; 34(1):82-7. View